Physician profile
Daniela Saadia
NPI 1629271390
$12,059.63
in general payments reported to CMS, 2019-2025
55 companies · $2,370 in 2025
The $2,370 reported for 2025 was more than what 75% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,108 · 2020: $1,175 · 2021: $1,529 · 2022: $1,510 · 2023: $2,112 · 2024: $2,257 · 2025: $2,370.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,498 · Education: $240.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,498.36 |
| Education | $240.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,498.00 | 2021-2025 | Qulipta, Ubrelvy, Botox |
| Lundbeck LLC | $814.15 | 2019-2025 | Rexulti, Vyepti |
| Lilly USA, LLC | $810.01 | 2019-2025 | Amyvid, Kisunla, Emgality |
| Teva Pharmaceuticals USA, INC. | $677.37 | 2019-2025 | Austedo Xr, Austedo Xr, Austedo |
| Amneal Pharmaceuticals LLC | $657.46 | 2020-2025 | Crexont, Rytary, Ongentys 50mg Capsules 30 |
| Amgen INC. | $613.80 | 2019-2022 | |
| Alexion Pharmaceuticals, INC. | $546.79 | 2022-2025 | Ultomiris |
| Pfizer INC. | $520.49 | 2022-2025 | |
| Eisai INC. | $465.18 | 2023-2025 | |
| Ucb, INC. | $442.80 | 2019-2025 | Briviact, Zilbrysq, Rystiggo |
| Neurocrine Biosciences, INC. | $397.59 | 2020-2025 | Ingrezza, Ongentys |
| Argenx US, INC. | $393.19 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Supernus Pharmaceuticals, INC. | $277.80 | 2019-2022 | |
| Allergan, INC. | $274.32 | 2019-2022 | |
| Genzyme Corporation | $260.63 | 2019-2023 |
Show all 55 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniela Saadia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.